Rescue/Salvage Therapy: Research
- Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients (March 11, 2013)
From AIDSmeds.com
 How Can "JAK Inhibitors" Help Salvage Patients and the Search for an HIV Cure? (January 15, 2013)
An interview with Raymond Schinazi, Ph.D., D.Sc.
From TheBodyPRO.com
- Management of Treatment-Experienced Patients: A Summary of Key CROI 2008 Research (February 11, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
- New Treatment Paradigms for Treatment-Experienced Patients (November 13, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here.
From Insight Medical Communications Inc.
On TheBodyPRO.com
- New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From TheBodyPRO.com
- Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From TheBodyPRO.com
- Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From TheBodyPRO.com
- Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
- Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com
- Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration
|
Advertisement
|
Email
Glossary
